Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and Increasing p21/p27 Levels

Nucleic Acid Therapeutics

Volumn 24, Issue 3, 2014, Pages 210-216

  Zheng, Xiangyu ^a,c   Wang, Yifang ^a,d   Liu, Ben ^a   Liu, Chunqing ^a   Liu, Dandan ^a   Zhu, Jie ^a   Yang, Chunhui ^a   Yan, Jiangzhou ^a   Liao, Xiaobo ^a   Meng, Xiuxiang ^a   Yang, Hong ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b LIAONING NORMAL UNIVERSITY   (China)

^c Henan Province Hospital of Traditional Chinese Medicine   (China)

^d Henan Blood Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; ORGAN SPECIFICITY; P21-ACTIVATED KINASES; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84900871810     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2013.0459     Document Type: Article

References (28)

1. ABBAS, T., and DUTTA, A. (2009). p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer. 9, 400-414.
2. AGARWAL, M.L., AGARWAL, A., TAYLOR, W.R., CHERNOVA, O., SHARMA, Y., and STARK, G.R. (1998). A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc. Natl. Acad. Sci. U. S. A. 95, 14775-14780.
3. BECKER, M., KORN, C., SIENERTH, A.R., VOSWINCKEL, R., LUETKENHAUS, K., CETECI, F., and RAPP, U.R. (2009). Polycomb group protein Bmi-1 is required for growth of RAF driven non-small-cell lung cancer. PLoS ONE 4, e4230.
4. BLANCO, A.C., RENNER, O., LEAL, J.F., and CARNERO, A. (2007). PTEN, more than the AKT pathway. Carcino-genesis 28, 1379-1386.
5. BREUER, R.H., SNIJDERS, P.J., SUTEDJA, G.T., SEWALT, R.G., and OTTE, A.P. (2005). Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squa-mous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48, 299-306.
6. CUI, H., MA, J., DING, J., LI, T., ALAM, G., and DING, H.F. (2006). Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J. Biol. Chem. 281, 34696-34704.
7. DOUGLAS, D., HSU, J.H., HUNG, L., COOPER, A., AB-DUEVA D., van DOORNINCK, J., PENG, G., SHIMADA, H., TRICHE, T.J., and LAWLOR, E.R. (2008). BMI-1 promotes Ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 68, 6507-6515.
8. ENGELMAN, J.A., LUO, J., and CANTLEY, L.C. (2006). The evolution of phosphatidyliositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619.
9. GLINSKY, G.V., BEREZOVSKA, O., and GLINSKII, A.B. (2005). Microarray analysis identifies a death from cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115, 1503-1521.
10. GUO, W.J., ZENG, M.S., YADAV, A., SONG, L.B., GUO, B.H., BAND, V., and DIMRI, G.P. (2007). Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and downregulating Akt activity in breast cancer cells. Cancer Res. 67, 5083-5089.
11. JACOBS, J.J., KIEBOOM, K., MARINO, S., DEPINHO, R.A., and VAN LOHUIZEN, M. (1999). The oncogene and Poly-comb group gene Bmi-1 regulates cell proliferation and senescence through the INK4a locus. Nature 397, 164-168.
12. KANG, M.K., KIM, R.H., KIM, S.J., YIP, F.K., SHIN K.H., DIMRI, G.P., CHRISTENSEN, R., HAN, T., and PARK, N.H. (2006). Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br. J.Cancer. 96, 126-133.
13. KIM, J.H., YOON, S.Y., KIM, C.N., JOO, J.H., MOON, S.K., CHOE, I.S., CHOE, Y.K., and KIM, J.W. (2004). The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 203, 217-224.
14. LESSARD, J.G. (2003). Bmi-1 determines the prolifera-tive capacity of normal and leukemic stem cells. Nature 423, 255-260.
15. LIU, S., DONTU, G., MANTLE, I.D., PATEL, S., and AHN, N.S. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071.
16. MALUMBRES, M., and BARBACID, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-156.
17. MENG, X.X., WANG, Y.F., ZHENG, X.Y., LIU, C.Q., SU, B.L., NIE, H.L., ZHAO, B.X., ZHAO, X.Y., and YANG, H. (2012). shRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis. Lung Cancer. 77, 24-30.
18. OKAMOTO, A., HUSSAIN, S.P., HAGIWARA, K., SPILLARE, E.A., RUSIN, M.R., DEMETRCK, D.J., SERRANO, M., HANNON, G.J., SHISEKJ, M., and ZARIWALA, M. (1995). Mutations in the P16INK4a/MTS1/CDKN2, and P18 genes in primary and metastatic lung cancer. Cancer Res. 55, 1448-1451.
19. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
20. SAWA, M., YAMAMOTO, K., YOKOZAWA, T., KIYOI, H., HISHIDA, A., KAJIGUCHI, T., SETO, M., KOHNO, A., KITAMURA, K., ITOH, Y., et al. (2005). Bmi-1 is highly expressed in Mo-subtype acute myeloid leukemia. Int. J. Hematol. 82, 42-47.
21. SONG, L.B., LI, J., LIAO, W.T., FENG, Y., and YU, C.P. (2009). The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119, 3626-3636.
22. SONG, L.B., ZENG, M.S., LIAO, W.T., ZHANG, L., and MO, H.Y. (2006). Bmi-1 is a novel molecular marker of naso-pharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 66, 6225-6232.
23. TASHIRO, E., TSUCHIYA, A., and IMOTO, M. (2007). Functions of cyclin D1 as an oncogene and regulation of Cyclin D1 expression. Cancer Sci. 98, 629-635.
24. TOYOOKA, S., TOKUMO, M., SHIGEMATSU, H., MATSUO, K., and ASANO, H. (2006). Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res. 66, 1371-1375.
25. VAN LOHUIZEN, M., VERBEEK, S., SCHEIJEN, B., WIENTJENS, E., and GULDEN, H. (1991). Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65, 737-752.
26. VIDAL, A., and Koff, A. (2000). Cell-cyclin inhibitors: three families united by common cause. Gene 247, 1-15.
27. WU, J., HU D., YANG, G., ZHOU, J., YANG, C., GAO, Y., and ZHU, Z. (2011). Down-regulation of Bmi-1 cooperates with Artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J. Cell. Biochem. 112, 1938-1948.
28. YU, Q., SU, B.L., LIU, D.D., LIU, B., and FAN, Y. (2007). Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides 17, 327-335.